Using agonists for iNKT cells in cancer therapy

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Alpha-galactosylceramide (α-GalCer) stimulates type I natural killer T (iNKT) cells for anti-cancer effects.
• Clinical translation is hindered by low iNKT cell frequencies and hypo-responsiveness in cancer patients.

Purpose of the Study:

• To review strategies for enhancing α-GalCer efficacy in cancer therapy.
• To explore novel approaches for iNKT cell-based cancer treatments.

Main Methods:

• Investigating ex vivo expansion of iNKT cells for adoptive therapy.
• Optimizing in vivo presentation of iNKT cell agonists via particulate vectors, structural modifications for CD1d binding, or recombinant CD1d attachment.
• Enhancing antigen-presenting cell (APC) licensing functions to induce adaptive immune responses.

Main Results:

• Encouraging clinical results reported for α-GalCer pulsed onto APCs.
• Preclinical studies focus on improving agonist presentation and APC licensing.
• A novel observation is the capacity of in vivo-activated iNKT cells to promote resident memory CD8+ T cell formation.

Conclusions:

• Despite challenges, α-GalCer and iNKT cell-based therapies hold promise for cancer treatment.
• Optimizing delivery and presentation of agonists are key areas of research.
• The induction of memory CD8+ T cells presents a new avenue for cancer immunotherapy.